Agenus, Inc. - נכסים נקיים למניה בודדת AGEN

The price trend for Agenus (AGEN) is based on the authority of this biopharmaceutical giant, which develops unique therapy regimens to activate the body's defenses against tumors. The current indicator stands at -4.70. Agenus is outpacing its competitors due to high patient survival rates in colorectal cancer treatment. Growth is driven by partnerships with global corporations integrating the firm's antibodies into their protocols.

For Agenus (AGEN), capital inflows from licensing agreements and milestones directly impact net assets, making the book value per share an indicator of financial stability for this biopharmaceutical leader. This metric is calculated as the difference between total assets and liabilities divided by the number of shares, reflecting the actual value of an investor's stake and the business's level of maturity through resource accumulation net of debt.